Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care

Summary

GL-ONC1 expanded access is for patients who are ineligible for an ongoing GL-ONC1 clinical trial. Expanded access is intended to treat individual patients with advanced stage cancers, including blood cancer, with no standard of care options for treatment. Potential patients will be evaluated individually depending on GL-ONC1 product supply.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications